What Is Obesity Hypoventilation Syndrome (OHS)?

Obesity hypoventilation syndrome (OHS) is a condition in which severe obesity leads to chronically inadequate breathing during waking hours, causing carbon dioxide to build up in the blood. Formally, it is defined by a body mass index of 30 or above combined with daytime arterial carbon dioxide levels at or above 45 mmHg, after ruling out other explanations for the underbreathing.¹ Once known as “Pickwickian syndrome,” OHS sits at the intersection of obesity, sleep-disordered breathing, and respiratory failure, yet it remains underdiagnosed and often confused with other conditions.

How Excess Weight Disrupts Breathing

The basic problem is mechanical. Fat accumulated around the chest wall and abdomen presses inward, reducing how far the lungs can expand. The diaphragm, the main breathing muscle, is physically impeded. Lung compliance drops, lower-airway resistance rises, and the small airways in the lung bases tend to close prematurely, trapping gas and creating areas where blood flows through lung tissue that is not being properly ventilated.² The result is a significant increase in the work it takes simply to breathe.³

People with OHS show a greater degree of this mechanical impairment than people at similar weight who do not develop the syndrome. Research has found that the diaphragm in obese individuals is thicker but paradoxically weaker, not because the muscle itself cannot generate force, but because the surrounding fat puts it at a mechanical disadvantage.⁴ People with obesity also tend to breathe more rapidly with shallower breaths to compensate for reduced lung compliance and the extra bulk around the torso. On top of this, ectopic fat deposited directly in the diaphragm muscle appears to cause lipid-related cellular stress, further weakening the muscle through biochemical pathways that compound the mechanical burden.⁵

Why the Brain Stops Compensating

Mechanical load alone does not fully explain OHS. Many extremely obese people never develop chronic carbon dioxide retention. A crucial second piece of the puzzle involves the brain’s respiratory control centers. Normally, when carbon dioxide rises, the brainstem ramps up breathing to blow it off. In OHS, this response is blunted.

Leptin, a hormone produced by fat tissue, plays a role in stimulating breathing drive. In severe obesity, leptin levels are very high, but the brain becomes resistant to leptin’s signals, much like insulin resistance in type 2 diabetes. Animal research has demonstrated that diet-induced obese mice develop resting hypoventilation and a weakened response to rising carbon dioxide, tied to disrupted leptin signaling in brainstem neurons responsible for detecting CO₂.⁶ So OHS is not purely a problem of the lungs or chest wall; the brain’s failure to increase breathing effort is a critical contributor.

How OHS Relates to Obstructive Sleep Apnea

OHS and obstructive sleep apnea (OSA) overlap heavily, but they are not the same condition. Most people with OHS also have OSA, where the upper airway collapses repeatedly during sleep. But the distinguishing feature of OHS is that the carbon dioxide elevation persists even when the person is awake and upright, not just during sleep. Patients with OHS can be classified into distinct phenotypes based on this overlap: those who have OHS with severe OSA, those who hypoventilate without significant obstructive events, and those who present with acute respiratory failure requiring hospitalization.⁷

The phenotype distinction matters clinically because treatment choices and prognosis differ. A patient whose carbon dioxide retention is driven mainly by severe OSA may respond well to simpler airway-pressure devices, while a patient who hypoventilates independently of airway obstruction often needs more aggressive ventilatory support. The acute hospitalized phenotype represents the most dangerous end of the spectrum, where the condition has gone unrecognized long enough to cause a crisis.

Cardiovascular Damage and Mortality

The slow buildup of carbon dioxide and the chronic low oxygen that accompany OHS take a serious toll on the heart and blood vessels. Pulmonary hypertension, elevated pressure in the arteries serving the lungs, is strikingly common. In one prospective study of 77 OHS patients referred to sleep clinics, roughly 69% had elevated pulmonary artery pressures, and about a quarter had severe pulmonary hypertension.⁸ Separate work using invasive catheterization found that over 40% of OHS patients met the formal threshold for pulmonary hypertension.⁹ Over time, the right side of the heart, which pumps blood through the lungs, enlarges and weakens under this sustained load.

Mortality rates reflect these cardiovascular consequences. A study comparing OHS patients with OSA patients found that roughly a quarter of those with OHS died during follow-up, compared with about 14% of those with OSA alone. The five-year mortality rate was about 16% for OHS versus under 5% for OSA. Cardiovascular disease accounted for nearly half of the deaths in the OHS group, including heart failure, sudden death, and stroke.¹⁰ The same study found that OHS patients had roughly twice the odds of dying and nearly twice the odds of experiencing a serious cardiovascular event compared with those who had OSA without daytime hypoventilation.

Beyond the heart and lungs, OHS is also associated with heightened systemic inflammation and metabolic dysfunction. Research comparing OHS patients with weight-matched controls found that markers of inflammation were substantially elevated in OHS, blood-vessel function was significantly impaired, and blood sugar control was worse, as measured by higher glycated hemoglobin.¹¹ This inflammatory milieu likely accelerates atherosclerosis and worsens insulin resistance, creating a feedback loop of metabolic and respiratory deterioration.

A Frequently Missed Diagnosis

One of the most striking features of OHS is how often it goes unrecognized. Because the symptoms overlap substantially with COPD, asthma, and heart failure, patients are frequently treated for those conditions for years before anyone checks a daytime carbon dioxide level. In one ICU cohort, 75% of patients admitted with what turned out to be severe OHS had been erroneously diagnosed and treated for COPD or asthma, and 86% had received diuretics for presumed congestive heart failure.¹² These patients had been admitted to the hospital an average of six times in the previous two years without anyone arriving at the correct diagnosis.

A larger cohort analysis found that 43% of OHS patients had been misdiagnosed with COPD, and none had been previously diagnosed with OHS.¹³ The same study reported that 37% had diabetes, underscoring the metabolic complexity of this population. The core problem is that when an obese patient presents with shortness of breath and carbon dioxide retention, clinicians may reflexively attribute these to chronic lung disease without considering that the obesity itself may be the primary driver.¹⁴

Screening Clues That Point Toward OHS

A definitive diagnosis of OHS requires an arterial blood gas (ABG) drawn while the patient is awake and breathing room air. But getting an ABG is invasive and not always convenient for screening. Researchers have found that a simpler blood test, serum bicarbonate, can serve as a useful screening tool. When the body chronically retains carbon dioxide, the kidneys compensate by holding on to more bicarbonate, so bicarbonate levels creep up. A calculated bicarbonate cutoff above 27 mmol/L had about 86% sensitivity and 90% specificity for identifying OHS in patients suspected of having sleep-disordered breathing, with a negative predictive value of roughly 96%.¹⁵ In practical terms, if the bicarbonate level is normal in an obese patient being evaluated for sleep apnea, OHS is unlikely. An elevated level warrants a full arterial blood gas to confirm.

This simple screening step could catch many of the patients currently slipping through the cracks, particularly those in sleep clinics who are being evaluated for OSA and already have overnight oximetry data showing prolonged dips in oxygen saturation.

Treatment With Positive Airway Pressure

The first-line treatment for OHS is positive airway pressure (PAP) delivered through a mask during sleep. Two main forms exist: CPAP, which delivers a single fixed pressure to keep the airway open, and noninvasive ventilation (NIV), which cycles between a higher pressure on inhalation and a lower pressure on exhalation, actively assisting ventilation. For years, NIV was considered the default because it directly augments the breathing effort that OHS patients struggle to generate on their own.

However, head-to-head trials have shown that for stable outpatients with OHS who also have severe OSA, the two approaches produce essentially the same outcomes. A large multicenter randomized trial found that CPAP and NIV had similar long-term effectiveness in improving gas exchange, daytime sleepiness, quality of life, and sleep-disordered breathing.¹⁶ A separate analysis confirmed no differences in mortality, cardiovascular events, or healthcare resource use between the two modalities.¹⁷ Because CPAP is simpler to set up, less expensive, and easier for patients to use, it is increasingly favored as the first-choice PAP therapy when severe OSA is present alongside OHS.

Further research has shown that even among patients with more severe baseline carbon dioxide elevations, long-term CPAP performed comparably to NIV in reducing daytime hypercapnia.¹⁸ The practical takeaway is that the decision between CPAP and NIV cannot be based on carbon dioxide severity alone; many patients who seem too sick for the simpler device do just as well on it.

Bariatric Surgery as a Potential Cure

Because OHS is fundamentally driven by excess body weight, substantial weight loss can resolve the condition entirely. Bariatric surgery offers the most dramatic and durable weight loss for people with severe obesity, and its effect on OHS can be profound. A retrospective study following patients for one year after metabolic bariatric surgery found that average BMI dropped from the severely obese range to about 29, and daytime carbon dioxide levels fell to near-normal. About 70% of patients achieved full resolution of OHS, defined as normal awake carbon dioxide levels and discontinuation of positive airway pressure therapy for at least six months.¹⁹

Surgery is not without risk, especially in patients who already have compromised respiratory and cardiovascular function. Perioperative management requires careful attention to airway pressure support and close monitoring in the days after surgery. Still, for patients who can safely undergo the procedure, it addresses the root cause in a way that PAP therapy alone cannot.

Why Supplemental Oxygen Can Be Dangerous

An important and counterintuitive risk involves supplemental oxygen. When a patient with OHS arrives at a hospital with low oxygen levels, the instinct is to give oxygen. But in people with chronic carbon dioxide retention, supplemental oxygen can paradoxically worsen hypoventilation and drive carbon dioxide levels even higher. A randomized crossover study found that commonly used oxygen concentrations caused significant rises in carbon dioxide and blood acidification in people with stable OHS.²⁰

Another crossover trial had to be stopped early in some participants breathing pure oxygen because their carbon dioxide rose dangerously fast. On average, supplemental oxygen reduced the amount of air patients breathed per minute and increased the proportion of each breath wasted on dead space rather than contributing to gas exchange.²¹ The mechanism involves both a reduction in the body’s drive to breathe when oxygen levels are artificially raised and changes in how blood flows through the lungs. For emergency and hospital clinicians, the lesson is clear: when you suspect OHS, treat with ventilatory support rather than oxygen alone, and if oxygen is needed, use the minimum amount necessary while monitoring carbon dioxide closely.

When OHS Presents as an Emergency

Some patients are never diagnosed until they arrive in acute respiratory failure. This happens when a chronic state of marginal compensation is tipped over the edge by an infection, surgery, sedating medication, or simply progressive weight gain. The presentation can be dramatic: altered consciousness, severe shortness of breath, and an inability to move independently. A published case described a 39-year-old man with a BMI above 81 who came to the emergency department with respiratory distress, altered mental status, and immobility, with blood gases showing severe carbon dioxide and oxygen derangement.²²

Acute presentations like this carry high mortality risk and often require intensive care, aggressive noninvasive ventilation, and sometimes intubation. A significant share of these emergency admissions could be prevented if OHS were identified earlier, during outpatient visits or routine sleep evaluations.

OHS in Children and Adolescents

With childhood obesity rates climbing worldwide, OHS is no longer exclusively an adult problem. In children and adolescents, the symptoms are subtle and easily attributed to being overweight or to behavioral issues: snoring, fragmented sleep, daytime sleepiness, morning headaches, poor concentration, and fatigue. The clinical picture overlaps so thoroughly with obstructive sleep apnea in children that OHS is frequently overlooked. In some cases, the condition is only recognized when a child presents with acute respiratory or cardiac decompensation.²³ Pediatricians evaluating severely obese children for sleep-disordered breathing should consider checking a venous blood gas or serum bicarbonate, particularly if overnight oximetry shows prolonged oxygen desaturation that seems disproportionate to the degree of upper-airway obstruction.

Emerging Drug Treatments on the Horizon

Currently, there are no medications approved specifically for OHS. Treatment revolves around PAP therapy and weight loss. But newer drugs developed for obesity and diabetes are generating interest. GLP-1 receptor agonists like semaglutide and tirzepatide produce substantial weight loss, and researchers have speculated that they could help OHS patients shed enough weight to improve or resolve their breathing dysfunction. Recombinant human leptin and orexin receptor antagonists are also on the radar as potential therapies, though none of these have been specifically studied in OHS populations yet.²⁴ Given the role of leptin resistance in blunting the brain’s breathing drive, therapies that restore leptin sensitivity could theoretically address the neurological component of OHS rather than just the mechanical one. Trials in this space would be welcomed, since the condition currently has no pharmacological option that targets its underlying biology.

From “Pickwickian Syndrome” to a Modern Definition

The condition was first described in the 1950s and named “Pickwickian syndrome” after a character in Charles Dickens’s novel The Pickwick Papers, a fat boy who fell asleep constantly. For decades, case reports blurred the line between OHS and obstructive sleep apnea, treating them as essentially the same thing.²⁵ It was not until 1999 that the American Academy of Sleep Medicine published a guideline formally separating OHS as its own entity, defined by the presence of daytime hypercapnia in an obese patient without another cause.²⁶ That four-decade gap between initial description and formal definition helps explain why the condition remains under-recognized today. Many clinicians trained before or during that transition period never developed the habit of screening for it, and the legacy of confusion with sleep apnea persists in clinical practice.